269 related articles for article (PubMed ID: 9554884)
21. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
[TBL] [Abstract][Full Text] [Related]
22. Highly sensitive and selective fluorescence assays for rapid screening of endothelin-converting enzyme inhibitors.
Luciani N; de Rocquigny H; Turcaud S; Romieu A; Roques BP
Biochem J; 2001 Jun; 356(Pt 3):813-9. PubMed ID: 11389689
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic and pharmacodynamic properties of SOL1: a novel dual inhibitor of neutral endopeptidase and endothelin converting enzyme.
Nelissen J; Lemkens P; Sann H; Bindl M; Bassissi F; Jasserand D; De Mey JG; Janssen BJ
Life Sci; 2012 Oct; 91(13-14):587-92. PubMed ID: 22365954
[TBL] [Abstract][Full Text] [Related]
24. Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications.
Jeng AY; Mulder P; Kwan AL; Battistini B
Can J Physiol Pharmacol; 2002 May; 80(5):440-9. PubMed ID: 12056551
[TBL] [Abstract][Full Text] [Related]
25. Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.
Jullien N; Makritis A; Georgiadis D; Beau F; Yiotakis A; Dive V
J Med Chem; 2010 Jan; 53(1):208-20. PubMed ID: 19899765
[TBL] [Abstract][Full Text] [Related]
26. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans.
Seed A; Kuc RE; Maguire JJ; Hillier C; Johnston F; Essers H; de Voogd HJ; McMurray J; Davenport AP
Life Sci; 2012 Oct; 91(13-14):743-8. PubMed ID: 22480515
[TBL] [Abstract][Full Text] [Related]
27. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme.
Battistini B; Daull P; Jeng AY
Cardiovasc Drug Rev; 2005; 23(4):317-30. PubMed ID: 16614731
[TBL] [Abstract][Full Text] [Related]
28. Rat big endothelin-1-induced bronchoconstriction and vasoconstriction in the isolated perfused rat lung: role of endothelin converting enzyme and neutral endopeptidase 24.11.
Held HD; Raschak M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 1997 May; 355(5):619-24. PubMed ID: 9151301
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and degradation of endothelin-1.
D'Orléans-Juste P; Plante M; Honoré JC; Carrier E; Labonté J
Can J Physiol Pharmacol; 2003 Jun; 81(6):503-10. PubMed ID: 12839262
[TBL] [Abstract][Full Text] [Related]
30. Soluble human endothelin-converting enzyme-1: expression, purification, and demonstration of pronounced pH sensitivity.
Ahn K; Herman SB; Fahnoe DC
Arch Biochem Biophys; 1998 Nov; 359(2):258-68. PubMed ID: 9808768
[TBL] [Abstract][Full Text] [Related]
31. Mapping the active site of endothelin-converting enzyme-1 through subsite specificity and mutagenesis studies: a comparison with neprilysin.
Johnson GD; Swenson HR; Ramage R; Ahn K
Arch Biochem Biophys; 2002 Feb; 398(2):240-8. PubMed ID: 11831855
[TBL] [Abstract][Full Text] [Related]
32. Diabetes-associated changes and role of N epsilon-(carboxymethyl)lysine in big ET-1-induced coronary vasoconstriction.
Matsumoto T; Ozawa Y; Taguchi K; Kobayashi T; Kamata K
Peptides; 2010 Feb; 31(2):346-53. PubMed ID: 19962413
[TBL] [Abstract][Full Text] [Related]
33. Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation.
Brands M; Ergüden JK; Hashimoto K; Heimbach D; Krahn T; Schröder C; Siegel S; Stasch JP; Tsujishita H; Weigand S; Yoshida NH
ChemMedChem; 2006 Jan; 1(1):96-105. PubMed ID: 16892341
[TBL] [Abstract][Full Text] [Related]
34. Structure of human endothelin-converting enzyme I complexed with phosphoramidon.
Schulz H; Dale GE; Karimi-Nejad Y; Oefner C
J Mol Biol; 2009 Jan; 385(1):178-87. PubMed ID: 18992253
[TBL] [Abstract][Full Text] [Related]
35. Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat.
Dai ZK; Hsieh CC; Chai CY; Wu JR; Jeng AY; Chou SH; Wu BN; Yeh JL; Chen IJ; Tan MS
Pediatr Pulmonol; 2010 Nov; 45(11):1076-85. PubMed ID: 20658482
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological characterization of a novel sulfonylureid-pyrazole derivative, SM-19712, a potent nonpeptidic inhibitor of endothelin converting enzyme.
Umekawa K; Hasegawa H; Tsutsumi Y; Sato K; Matsumura Y; Ohashi N
Jpn J Pharmacol; 2000 Sep; 84(1):7-15. PubMed ID: 11043447
[TBL] [Abstract][Full Text] [Related]
37. Mutagenesis of Glu403 to Cys in rabbit neutral endopeptidase-24.11 (neprilysin) creates a disulphide-linked homodimer: analogy with endothelin-converting enzyme.
Hoang MV; Sansom CE; Turner AJ
Biochem J; 1997 Nov; 327 ( Pt 3)(Pt 3):925-9. PubMed ID: 9581575
[TBL] [Abstract][Full Text] [Related]
38. Disulfide bonds in big ET-1 are essential for the specific cleavage at the Trp(21)-Val(22) bond by soluble endothelin converting enzyme-1 from baculovirus/insect cells.
Fahnoe DC; Johnson GD; Herman SB; Ahn K
Arch Biochem Biophys; 2000 Jan; 373(2):385-93. PubMed ID: 10620363
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of novel substituted pyridines as inhibitors of endothelin converting enzyme-1 (ECE-1).
Massa MA; Patt WC; Ahn K; Sisneros AM; Herman SB; Doherty A
Bioorg Med Chem Lett; 1998 Aug; 8(16):2117-22. PubMed ID: 9873497
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological activity of novel potent endothelin-converting enzyme-1 inhibitors.
Firooznia F; Gude C; Chan K; Fink CA; Qiao Y; Satoh Y; Marcopoulos N; Savage P; Beil ME; Bruseo CW; Trapani AJ; Jeng AY
Bioorg Med Chem Lett; 2001 Feb; 11(3):375-8. PubMed ID: 11212114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
